Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:LEGN NASDAQ:LNTH NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$45.62+0.4%$50.09$21.34▼$58.40$3.74B-0.24934,066 shs905,913 shsLEGNLegend Biotech$35.95+5.1%$37.85$27.34▼$57.94$6.41B0.28957,020 shs1.10 million shsLNTHLantheus$55.15-0.3%$67.66$47.25▼$118.21$3.73B0.152.57 million shs883,949 shsRVMDRevolution Medicines$39.77+0.6%$37.23$29.17▼$62.40$7.10B1.122.02 million shs1.79 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-2.76%-5.57%-6.06%-14.25%+67.06%LEGNLegend Biotech-1.47%-2.45%-11.80%+12.71%-40.54%LNTHLantheus+0.71%-0.66%-21.65%-30.57%-48.07%RVMDRevolution Medicines+4.11%+6.04%+7.92%-2.11%-7.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.906 of 5 stars3.51.00.04.74.10.80.0LEGNLegend Biotech3.5236 of 5 stars4.53.00.00.02.71.70.6LNTHLantheus4.8903 of 5 stars4.33.00.04.23.42.51.9RVMDRevolution Medicines4.4698 of 5 stars4.51.00.04.74.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$81.5778.81% UpsideLEGNLegend Biotech 2.91Moderate Buy$74.22106.46% UpsideLNTHLantheus 2.67Moderate Buy$91.6066.09% UpsideRVMDRevolution Medicines 3.00Buy$69.9275.82% UpsideCurrent Analyst Ratings BreakdownLatest AKRO, RVMD, LNTH, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$66.008/25/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$77.00 ➝ $78.008/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$75.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$67.008/12/2025LEGNLegend BiotechRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$75.00 ➝ $77.008/12/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$81.00 ➝ $83.008/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$120.00 ➝ $70.008/7/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$57.00 ➝ $56.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$12.82 per shareN/ALEGNLegend Biotech$627.24M10.58N/AN/A$5.64 per share6.37LNTHLantheus$1.53B2.44$7.13 per share7.74$17.16 per share3.21RVMDRevolution Medicines$11.58M641.99N/AN/A$9.98 per share3.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)LNTHLantheus$312.44M$3.7614.678.74N/A17.82%34.06%19.10%11/5/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)Latest AKRO, RVMD, LNTH, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0212.6612.66LEGNLegend Biotech0.304.714.57LNTHLantheus0.494.294.07RVMDRevolution Medicines0.1311.7911.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ALEGNLegend Biotech70.89%LNTHLantheus99.06%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%LEGNLegend Biotech0.02%LNTHLantheus2.00%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableLNTHLantheus70067.99 million66.63 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableAKRO, RVMD, LNTH, and LEGN HeadlinesRecent News About These CompaniesParadigm Biocapital Advisors LP Sells 375,000 Shares of Revolution Medicines, Inc. $RVMDSeptember 2 at 7:09 AM | marketbeat.comRevolution Medicines, Inc. $RVMD Stock Holdings Increased by Magnetar Financial LLCSeptember 2 at 6:04 AM | marketbeat.comLandscape Capital Management L.L.C. Buys Shares of 17,213 Revolution Medicines, Inc. $RVMDSeptember 2 at 5:42 AM | marketbeat.comB. Metzler seel. Sohn & Co. AG Acquires 8,622 Shares of Revolution Medicines, Inc. $RVMDSeptember 2 at 5:14 AM | marketbeat.comRaymond James Financial Inc. Sells 17,994 Shares of Revolution Medicines, Inc. $RVMDSeptember 2 at 3:53 AM | marketbeat.comOppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy ProgressSeptember 2 at 2:10 AM | insidermonkey.comRevolution Medicines, Inc. $RVMD is DAFNA Capital Management LLC's 3rd Largest PositionSeptember 1 at 7:14 AM | marketbeat.comWalleye Capital LLC Has $1.43 Million Position in Revolution Medicines, Inc. $RVMDSeptember 1 at 4:24 AM | marketbeat.comRevolution Medicines, Inc. $RVMD Shares Sold by Rafferty Asset Management LLCAugust 31 at 5:21 AM | marketbeat.comTema Etfs LLC Grows Holdings in Revolution Medicines, Inc. $RVMDAugust 30, 2025 | marketbeat.comComerica Bank Boosts Stock Holdings in Revolution Medicines, Inc. $RVMDAugust 30, 2025 | marketbeat.comAmeriprise Financial Inc. Has $52.71 Million Holdings in Revolution Medicines, Inc. $RVMDAugust 30, 2025 | marketbeat.com18,505 Shares in Revolution Medicines, Inc. $RVMD Purchased by CW Advisors LLCAugust 29, 2025 | marketbeat.comInvesco Ltd. Has $6.73 Million Stock Holdings in Revolution Medicines, Inc. $RVMDAugust 29, 2025 | marketbeat.comRevolution Medicines, Inc. $RVMD Shares Sold by Price T Rowe Associates Inc. MDAugust 27, 2025 | marketbeat.comHsbc Holdings PLC Sells 49,106 Shares of Revolution Medicines, Inc. $RVMDAugust 27, 2025 | marketbeat.com1,673,429 Shares in Revolution Medicines, Inc. $RVMD Acquired by T. Rowe Price Investment Management Inc.August 25, 2025 | marketbeat.comAmerican Century Companies Inc. Buys 100,214 Shares of Revolution Medicines, Inc. $RVMDAugust 25, 2025 | marketbeat.comNuveen LLC Invests $16.90 Million in Revolution Medicines, Inc. $RVMDAugust 23, 2025 | marketbeat.comQ3 Earnings Forecast for RVMD Issued By Lifesci CapitalAugust 22, 2025 | marketbeat.comRevolution Medicines, Inc. $RVMD Shares Acquired by Wellington Management Group LLPAugust 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKRO, RVMD, LNTH, and LEGN Company DescriptionsAkero Therapeutics NASDAQ:AKRO$45.62 +0.18 (+0.40%) Closing price 04:00 PM EasternExtended Trading$45.62 0.00 (-0.01%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Legend Biotech NASDAQ:LEGN$35.95 +1.73 (+5.06%) Closing price 04:00 PM EasternExtended Trading$36.06 +0.10 (+0.29%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Lantheus NASDAQ:LNTH$55.15 -0.14 (-0.25%) Closing price 04:00 PM EasternExtended Trading$55.72 +0.57 (+1.03%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Revolution Medicines NASDAQ:RVMD$39.77 +0.24 (+0.61%) Closing price 04:00 PM EasternExtended Trading$39.88 +0.11 (+0.27%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
